Dawn French
Acute Care · Alliance, OHNPI 1124358254
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,769 of the $40,466 with a category attached, or 76.0%. 34 manufacturers reported payments, led by AbbVie at 38.0% of the total. Reporting peaked in 2022 at $11,424 and has fallen 63.9% since, to $4,125 in 2025. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 603 payments — averaging $67.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$15K
- Nestle Healthcare Nutrition Inc.$9K
- Aimmune Therapeutics, Inc.$7K
- Ironwood Pharmaceuticals, Inc$4K
- Johnson & Johnson$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$703
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$30,76976%
- Travel & lodging$3121%
- Food & beverage$9,19123%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 217 | $15,381 |
| Nestle Healthcare Nutrition Inc. | 54 | $9,049 |
| Aimmune Therapeutics, Inc. | 26 | $6,817 |
| Ironwood Pharmaceuticals, Inc | 31 | $4,202 |
| Johnson & Johnson | 53 | $1,057 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 50 | $703 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $411 |
| Gilead | 15 | $346 |
| Intercept Pharmaceuticals, Inc. | 20 | $342 |
| Bristol Myers Squibb | 25 | $342 |
| Sanofi | 7 | $267 |
| Ardelyx, Inc. | 11 | $221 |
| Ipsen Biopharmaceuticals, Inc | 9 | $184 |
| Ferring Pharmaceuticals Inc. | 11 | $168 |
| Merck | 9 | $159 |
| Regeneron Healthcare Solutions, Inc. | 3 | $114 |
| Evoke Pharma, Inc. | 4 | $85 |
| Phathom Pharmaceuticals, Inc. | 4 | $75 |
| Madrigal Pharmaceuticals | 3 | $68 |
| Vivus LLC | 4 | $68 |
| Amgen | 3 | $48 |
| Lilly USA, LLC | 2 | $48 |
| Pfizer | 2 | $46 |
| Novo Nordisk | 2 | $36 |
| Redhill Biopharma Inc. | 2 | $32 |
| Celltrion USA Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $27 |
| Organon | 2 | $26 |
| Braintree Laboratories, Inc. | 2 | $26 |
| Boehringer Ingelheim | 1 | $22 |
| Exact Sciences | 1 | $18 |
| UCB, Inc. | 1 | $16 |
| Sandoz | 1 | $16 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,466 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 65 | $323,294 |
| SimponiGolimumab | 35 | $266,195 |
| RinvoqUpadacitinib | 26 | $214,248 |
| XifaxanRifaximin | 55 | $196,767 |
| CreonLipase/Protease/Amylase | 63 | $178,259 |
| Humira(Cf) PenAdalimumab | 20 | $149,889 |
| Cimzia (2 Pack)Certolizumab Pegol | 18 | $102,551 |
| LinzessLinaclotide | 103 | $85,159 |
| TrulancePlecanatide | 49 | $34,547 |
| Famotidine | 1,002 | $13,565 |
| MotegrityPrucalopride Succinate | 17 | $12,677 |
| Omeprazole | 944 | $11,799 |
| VoqueznaVonoprazan Fumarate | 18 | $10,122 |
| Mesalamine | 44 | $9,639 |
| Pantoprazole Sodium | 850 | $9,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Creon, Linzess | $15,381 | $477,666192 claims |
| Aimmune Therapeutics, Inc.Zenpep | $6,817 | $323,29465 claims |
| Johnson & JohnsonSimponi | $1,057 | $266,19535 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $703 | $231,314104 claims |
| UCB, Inc.Cimzia (2 Pack) | $16 | $102,55118 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $411 | $12,67717 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $75 | $10,12218 claims |
| SandozLansoprazole | $16 | $1,67438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Alliance
- Andrea RobinsonCleveland$149K
- Brittney BrowneMonroe$142K
- Jamie McGuireMiamisburg$86K
- Ileah ReichertColumbus$73K
- Davida PraterBeavercreek$46K
- Holly McKibbenColumbus$23K
- Jody HussBlue Ash$13K
- Julie LurieCincinnati$13K
- Susan BrooksMount Vernon$11K
- Laura WellsChillicothe$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.